Dementia with Lewy bodies is a devastating disorder, combining some of the worst features of Alzheimer’s and Parkinson’s, but it is relatively rare and often goes unrecognized. DLB research has lagged far behind that for AD and PD, but is rapidly gaining ground. At a recent conference in Las Vegas, researchers discussed worldwide progress in building the infrastructure to support large longitudinal studies and clinical trials for DLB. Researchers presented guidelines for improving diagnosis and management of the disease, and scientists discussed how best to identify prodromal cases for research studies.
A U.K. research program developed guidelines for clinical practice. In preliminary studies, it boosted diagnosis and improved patient care.
The field is rapidly building the infrastructure for biomarker studies and large clinical trials.
The field is searching for a combination of clinical features and biomarkers that will identify the disease in people with mild cognitive impairment.